US 11,806,386 B2
Type I diabetes therapy
Helen E. Thomas, Fitzroy (AU); Thomas W. H. Kay, Fitzroy (AU); Balasubramanian Krishnamurthy, Fitzroy (AU); and Gaurang Jhala, Fitzroy (AU)
Assigned to St. Vincent's Institute of Medical Research, Fitzroy (AU)
Appl. No. 16/637,304
Filed by St. Vincent's Institute of Medical Research, Fitzroy (AU)
PCT Filed Aug. 7, 2018, PCT No. PCT/AU2018/050823
§ 371(c)(1), (2) Date Feb. 7, 2020,
PCT Pub. No. WO2019/028503, PCT Pub. Date Feb. 14, 2019.
Claims priority of application No. 2017903125 (AU), filed on Aug. 7, 2017.
Prior Publication US 2020/0345815 A1, Nov. 5, 2020
Int. Cl. A61K 38/28 (2006.01); A61P 3/10 (2006.01); A61K 31/437 (2006.01); A61K 31/4985 (2006.01); A61K 31/519 (2006.01); A61K 31/529 (2006.01); A61K 31/5355 (2006.01); A61K 31/541 (2006.01); A61K 31/553 (2006.01); A61K 38/17 (2006.01); A61K 38/46 (2006.01); A61K 38/51 (2006.01)
CPC A61K 38/28 (2013.01) [A61K 31/437 (2013.01); A61K 31/4985 (2013.01); A61K 31/519 (2013.01); A61K 31/529 (2013.01); A61K 31/5355 (2013.01); A61K 31/541 (2013.01); A61K 31/553 (2013.01); A61K 38/1709 (2013.01); A61K 38/465 (2013.01); A61K 38/51 (2013.01); A61P 3/10 (2018.01)] 11 Claims
 
1. A method of delaying the onset of type 1 diabetes (T1D) in an individual having or at risk of having T1D, the method comprising providing in the individual:
an anti-inflammatory compound; and
a pancreatic autoantigen or a derivative or variant thereof;
thereby delaying the onset of T1D in the individual;
wherein the anti-inflammatory compound is Ruxolitinib, and
wherein the pancreatic autoantigen is proinsulin or a derivative or variant thereof.